Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Income
$5.8M
Filings
302
Unique Clients
16
Active Period
2009–2016
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
21st Century Cures Act
2016 · second_quarter · Client: INTEGRA LIFESCIENCES CORP.
H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 6
H.R. 6, the "21st Century Cures Act." Policy issues relating Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically Section 902 relating to the Breakthrough Therapy Designation for pharmaceuticals.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6
21st Century Cures Act
2016 · second_quarter · Client: ARALEZ PHARMACEUTICALS US INC (FORMERLY POZEN INC )
H.R. 6, the "21st Century Cures Act," specifically policy issues relating to combination pharmaceutical products.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 6
Reforming Access for Investments in Startup Enterprises Act of 2015 or the RAISE Act of 2015
2016 · second_quarter · Client: NASDAQ (FORMERLY NASDAQ OMX GROUP)
Policy issues relating to transparency and conflicts of interest in the financial services' proxy advisory industry, and capital markets structure. H.R. 1839, the "Reforming Access for Investments in Startup Enterprises Act."
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1839
Food and Drug Administration Safety Over Sequestration Act of 2015
2016 · second_quarter · Client: CELGENE CORPORATION
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1078
Patients' Access to Treatments Act of 2015
2016 · second_quarter · Client: CELGENE CORPORATION
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1600
Cancer Drug Coverage Parity Act of 2015
2016 · second_quarter · Client: CELGENE CORPORATION
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2739
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2841
Family Cord Blood Banking Act
2016 · second_quarter · Client: CELGENE CORPORATION
H.R. 3982, the "Family Cord Blood Banking Act." Policy issues relating to corporate tax reform.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3982
Family Cord Blood Banking Act
2016 · second_quarter · Client: CELGENE CORPORATION
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3982
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6
H.R. 9, the "Innovation Act," specifically those sections relating to amending the Inter Partes Review process.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 9
Cancer Drug Coverage Parity Act of 2015
2016 · second_quarter · Client: CELGENE CORPORATION
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."
Client expense: — · Firm income: $30,000
Matched citations: S.1566
H.R. 6, the "21st Century Cures Act." H.R. 512, the "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act." S. 145, the "Promise for Antibiotics and Therapeutics for Health Act." S. 275, the "Medicare Home Infusion Site of Care Act." Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 512
H.R. 6, the "21st Century Cures Act." H.R. 512, the "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act." S. 145, the "Promise for Antibiotics and Therapeutics for Health Act." S. 275, the "Medicare Home Infusion Site of Care Act." Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6
H.R. 6, the "21st Century Cures Act." H.R. 512, the "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act." S. 145, the "Promise for Antibiotics and Therapeutics for Health Act." S. 275, the "Medicare Home Infusion Site of Care Act." Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification.
Client expense: — · Firm income: $30,000
Matched citations: S. 145
Medicare Home Infusion Site of Care Act of 2015
2016 · second_quarter · Client: THE MEDICINES COMPANY
H.R. 6, the "21st Century Cures Act." H.R. 512, the "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act." S. 145, the "Promise for Antibiotics and Therapeutics for Health Act." S. 275, the "Medicare Home Infusion Site of Care Act." Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification.
Client expense: — · Firm income: $30,000
Matched citations: S. 275
North American Energy Security and Infrastructure Act of 2015
2016 · second_quarter · Client: PUBLIC SERVICE ENTERPRISE GROUP
S. 2012, the "Energy Policy Modernization Act." H.R. 8, the "North American Energy Security and Infrastructure Act."
Client expense: — · Firm income: $20,000
Matched citations: H.R. 8
North American Energy Security and Infrastructure Act of 2016
2016 · second_quarter · Client: PUBLIC SERVICE ENTERPRISE GROUP
S. 2012, the "Energy Policy Modernization Act." H.R. 8, the "North American Energy Security and Infrastructure Act."
Client expense: — · Firm income: $20,000
Matched citations: S. 2012
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. H.R. 6, the "21st Century Cures Act."
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6
Food and Drug Administration Safety Over Sequestration Act of 2015
2016 · second_quarter · Client: C.R. BARD INC.
H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 160, the"Protect Medical Innovation Act. S. 149, the "Medical Device Access and Innovation Protection Act." S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1078
Protect Medical Innovation Act of 2015
2016 · second_quarter · Client: C.R. BARD INC.
H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 160, the"Protect Medical Innovation Act. S. 149, the "Medical Device Access and Innovation Protection Act." S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 160
Protect Medical Innovation Act of 2015
2016 · second_quarter · Client: C.R. BARD INC.
H.R. 160, the Protect Medical Innovation Act. S.149, the Medical Device Access and Innovation Protection Act. H.R. 880, the American Research and Competitiveness Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 160
Defending Public Safety Employees' Retirement Act
2016 · second_quarter · Client: C.R. BARD INC.
H.R. 2146, the "Trade Preferences Extension Act." Policy issues relating to the Trans-Pacific Partnership trade agreement.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2146
H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 160, the"Protect Medical Innovation Act. S. 149, the "Medical Device Access and Innovation Protection Act." S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6
Source: Senate LDA